Giredestrant - Genentech
Alternative Names: GDC-9545; RG-6171; RO-7197597Latest Information Update: 09 Jul 2024
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Azetidines; Fluorobenzenes; Indoles; Piperidines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer; HER2 positive breast cancer
- Phase II Endometrial cancer
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Efficacy, adverse events and drug interaction data from a phase I/II trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 10 May 2024 Roche plans to file regulatory application for HER2 negative breast cancer (Second-line therapy or greater, Combination therapy) in or after 2027 (Roche pipeline, May 2024)
- 09 May 2024 Chugai Pharmaceutical plans to file regulatory filing for Breast cancer (Adjuvant therapy) in or after 2027 (Roche pipeline, May 2024)